SUMMARY Two boys who were immobilised with peripheral neuropathy developed hypercalcaemia. It is suggested that hypercalcaemia aggravated the muscle weakness as well as producing systemic upset. The hypercalcaemia was controlled with corticosterioids which had to be continued over several months. A satisfactory remission of the disease occurred in both cases. The hypercalcaemia was attributed to immobility in young people with rapid calcium turnover in bone.
Immobilisation hypercalcaemia is an unusual condition which occurs predominantly in adolescent males. 2 The majority of reports describe it in association with trauma and fractures.3" We report two adolescent males with peripheral neuropathy who developed this syndrome, which resulted in systemic malaise and increased disability.
Case I An 11-year-old schoolboy presented with a history of generalised malaise, weight loss and an unproductive cough. Two weeks after these symptoms began he developed paraesthesiae in his hands and feet, and then progressive weakness. This began in one hand and later became generalised, involving proximal and distal muscle groups of all limbs. There was truncal weakness, but no respiratory embarrassment and no cranial nerve deficit. He was areflexic but there was no sensory loss. Over the next five days his power diminished but at his weakest he was able to stand unaided although he could not walk (week 3, fig 1) . Over the course of the next few weeks he progressively improved and he was discharged from hospital at the end of 5 weeks, able to walk slowly and unsteadily, but without assistance. A peripheral eosinophilia (0-63 x 109/ 1) found on admission, later resolved. The serum antibody titre was 1/640 against mycoplasma pneumoniae. The CSF contained no cells and the protein content was 0-54 g/l (N < 0-4 g/l). Urinary prophyrins were not detected. Motor nerve conduction velocities were reduced (35 m/s in the right common peroneal nerve). The diagnosis was the Guillain-Barre syndrome secondary to a mycoplasma infection. Hypercalcaemia was noted during week 5, and he vomited on one occasion at that time. With increasing mobility, the serum calcium seemed to be falling and when first discharged from hospital he had no symptoms suggesting hypercalcaemia. He was re-admitted at the end of week 6 with a 48 hour history of persistent vomiting, general malaise and markedly increased weakness. By the time of admission, he was unable to stand, and by 3 days later, he was unable to sit in bed unaided and had developed a bilateral wrist and foot drop. The serum calcium levels at that time are illustrated in fig 1; Immobilisation hypercalcaemia complicating polyneuropathy in adolescent boys Treatment with tetracosactrin was followed by a rapid fall in the serum calcium cessation of vomiting and improvement in his muscle power so that by the end of week 16 he was feeding himself. The steroid was progressively reduced, and by the end of week 18 he was sufficiently well to be discharged home, on no treatment.
At home, the vomiting soon returned and he became progressively weaker. By the middle of week 19 he was again unable to feed himself and the serum calcium had risen to 3-3 mmol/l. At the time of the highest serum calcium, parathormone was 0-25 1g/l (N < 0-6,ig/l), the Minimal upper and lower limb girdle weakness alkaline phosphatase level was 87 U/l (N 20-85 U/I), there was no renal impairment and thyroid function tests were normal. The serum calcium was temporarily depressed by an injection of 50 IU calcitonin but returned to its previous level within twenty-four hours. Tetracosactrin therapy was resumed and he responded well. The serum calcium returned to normal and remained so although steroids had to be continued for a total of six months to maintain it. By week 24 he was again able to feed himself, by week 27 he was walking unsteadily unaided and has continued to improve since. Eighteen months from the onset of his illness there was only slight weakness of movements at the hip girdle and shoulder girdle.
Discussion
Extensive investigation of both patients failed to reveal any cause of their hypercalcaemia other than immobility. Hypercalcaemia may occur during prolonged immobilisation in any condition associated with increased bone turnover. ' We have been unable to find any report of the development of this syndrome in patients with peripheral neuropathy although it was recognised many years ago that children immobilised by acute paralytic poliomyelitis occasionally develop hypercalcaemia.312 13 In the healthy individual there is a balance between the resorption and the formation of bone which is influenced by age, nutritional and hormonal factors as well as the degree of physical activity. Osteoblastic activity is thought to be stimulated by mechanical stress. If such stress is removed by immobilisation then bone formation is reduced, leaving a relative excess of bone destruction causing the release of calcium into the extracellular fluid.
Under normal circumstances, this increase in extracellular calcium concentration is compensated for by increased urinary calcium excretion maintaining normal serum calcium concentrations. Normal adult volunteers develop increased urinary calcium excreWalls, Ashworth, Saunders tion two to three days after the onset of enforced immobilisation which increases to a peak four weeks later, remaining at this peak level until two to three weeks after remobilisation occurs when it begins to fall again. '4 Similar patterns have been observed in adults immobilised by fractures'5 and by poliomyelitis. ' 2 At times of high bone turnover, any sudden reduction in osteoblast activity causes massive release of calcium into the extracellular fluid which overwhelms renal excretion, hypercalcaemia follows which in itself impairs renal excretion of calcium and sodium and water absorption from the proximal renal tubule. The serum calcium therefore progressively rises in the potentially disastrous spiral of disequilibrium hypercalcaemia. ' When hypercalcaemia is secondary to immobilisation, programmes of assisted weight bearing should be instituted when practicable, but if these are insufficient to reduce the serum calcium to normal then steroids or calcitonin are the most effective form of treatment." Both our patients responded dramatically to small doses of steroids, with immediate cessation of symptoms. Prolonged treatment however was necessary and when steroids were withdrawn early (case 2), rebound symptomatic hypercalcaemia was associated with a temporary increase in weakness which resolved when steroids were re-introduced. In case 1, there was marked permanent increase in weakness when symptomatic hypercalcaemia occurred, which did not resolve when the serum calcium was reduced to normal. This may have been due to axonal damage as there was no change in the nerve conduction velocities following his deterioration. The patient's functional recovery was considerably delayed and his residual deficit may be permanent.
Controlled trials have failed to demonstrate any therapeutic benefit from steroid treatment in the Guillain-Barre syndrome and have even suggested that such treatment may increase eventual functional disability. '6 The prolonged evolution of the weakness in case 2 suggested that he had a more chronic inflammatory polyneuropathy. It is generally accepted that a significant proportion of patients with this condition respond to treatment with steroids. '7 There are however well documented cases with the same syndrome who do not respond to steroid treatment. '8 '9 There are few records of serum calcium levels among the reports of chronic inflammatory neuropathies in the literature. Where the serum calcium level is documented it is persistently normal. We have found no record of hypercalcaemia associated with symptomatic relapse in this condition and no description of functional deterioration in patients with the Guillain-Barre syndrome associated with Immobilisation hypercalcaemia complicating polyneuropathy in adolescent boys hypercalcaemia. From our experience we feel that immobilisation hypercalcaemia is an indication for steroid therapy in both these conditions. We suggest that all patients immobilised at times of increased bone turnover should have their serum calcium monitored. Treatment should be given at an early stage and may need to be continued over a prolonged period.
Immobilisation hypercalcaemia is not a benign entity. It may be associated with relatively nonspecific symptoms initially but if left untreated the patient may go on to develop fits, encephalopathy or may even die.7 In the past, it has been confused with hyerparathyroidism and has led to unnecessary surgical exploration of the neck.3 In both of our cases, it significantly increased the duration of their functional disability. In case 1, it appeared to cause irreversible worsening of the peripheral neuropathy.
